top of page

Revolutionizing biotech with the power of artificial intelligence


person in scrubs squeezing blue liquid from one tube into another, biotech

As we continue to move forward into the new year, we are looking at the ways AI continues to revolutionize the world around us. As AI intersects with the realm of biotechnology, it fuels curiosity and wonder as to what breakthroughs will come about. More and more companies are implementing AI into biotech, and even more research will continue to be done each year. In fact, the global AI in biotechnology market size accounted for USD 4.70 billion in 2024, grew to USD 5.60 billion in 2025, and is expected to be worth around USD 27.43 billion by 2034.



Big Tech shows interest in AI’s future in biotech


Where new transformations in AI are predicted, it can be expected that several major tech companies will want to become stakeholders in that research. These include Nvidia, Google, Microsoft, Amazon, and Salesforce. The force of these companies and the money that they are putting into AI biotech research is certainly a big factor in the increasing market size. 


Big Tech has invested billions of dollars into AI biotech research, believing in the potential breakthroughs that could come of it. Google’s DeepMind unveiled AlphaFold, which is a tool that can predict protein structures, and Amazon, Microsoft, and Salesforce ventured into protein research as well. The large datasets that train the AI and the capabilities of the AI algorithms make it a powerful tool for gaining more insights into the building blocks of sentient life. Using this research, we can usher in new innovations in drug development. Some discoveries may even contribute to the lengthening of human life by tackling age-related diseases.



Groundbreaking research to lengthen human lifespan


An AI-powered company called Retro Biosciences is in the process of developing drugs and therapies for age-related diseases like Alzheimer’s. OpenAI CEO Sam Altman is one of the investors in this project, forming a partnership to utilize advanced technology for this research. The AI is used to design proteins that can temporarily turn regular cells into stem cells, which can reverse the aging process, according to Retro Biosciences. Additionally, their lab is working on cell therapies for rejuvenating blood and brain cells, which is a huge breakthrough for treating Alzheimer’s. They plan to develop and release their first drug in the next few years.



Additional trends for AI in biotech


In addition to the AI-powered drug discovery and stem cell therapies stated above, there are more trends emerging for AI in biotech. These include:


  • Personalized medicine: AI in biotech is allowing for more personalized approaches to treatments, rather than a one-size-fits-all strategy. Using data for genetic profiles, patient lifestyles, and surrounding environments, treatments can be tailored to a specific patient, increasing their effectiveness. 


  • Synthetic biology: AI is also being used for gene editing, biomaterial production and synthetic pathways; this combines biology and engineering to generate new biological entities.


  • Data integration: Advanced platforms are being developed in order to store and manage vast amounts of genomic, proteomic and clinical data, which is critical for AI in biotech. Having a more holistic view of patient data enables more accurate diagnoses and personalized medicine, as mentioned previously.



AI in biotech has the potential for many great discoveries in improving patient outcomes. Developments in treating diseases that were previously thought to be impossible are now seeing tremendous breakthroughs due to our advancements in artificial intelligence.







Sources:

Comments


Locations: Edison, NJ | Philadelphia, PA | Memphis, TN

HQ: 860 US Route 1 N. Suite 102

Edison, NJ 08817

info@sednacg.com

  • Instagram
  • Facebook
Stay Connected With Sedna!

Thanks for submitting!

bottom of page